The portal has been in development over the past few months. The new submission portal will improve the communication timelines between SAHPRA and applicants. The app also allows the end user to perform the following tasks:
Create a user account, manage the user account.
Submit an application (applications submitted cannot be edited).
Receive feedback and notifications via email.
Track the status of your application.
The portal must only be accessed via the e-services tab on SAHPRA’s homepage.
There are four categories of Section 21 applications that can be submitted through the portal:
Approved under the “IVERMECTIN CONTROLLED COMPASSIONATE USE PROGRAMME”
|Product||Manufacturing site||Imported by|
|Alice™||Square Pharmaceuticals (Bangladesh)||Forrester Pharma (Pty)/Lamar International|
|Parakil™||Incepta Pharmaceuticals Ltd (Bangladesh)||RX Medicals (Pty) Ltd.|
|Parakil™||Incepta Pharmaceuticals Ltd (Bangladesh)||Trinity Pharma (Pty) Ltd|
|Invermectin tablets USP||Ingenus Pharmaceuticals NJ, LCC (New Jersey)||RX Medicals (Pty) Ltd.|
|Stromectol™ MSD||(Kenya,US, France)||Equity Pharmaceuticals|
|Ivermectin||Kwality Pharmaceutical (India)||Equity Pharmaceuticals|
|Ivermex||EUROPEENNE DE PHARMACOTECHNIE - EUROPHARTECH rue Henri Matisse, 63370 Lempdes ,France||Haempharma (Pty) Ltd|